Advanced Certification in Pharmacovigilance Aggregate Report

Explore essential documents for dsur and pbrer, including protocol, investigator brochure, smpc, company code data sheet, us package inserts, and rmp; learn safety monitoring, signal detection, and ird list concepts.

Explore strategies for preparing DSURs for multi-drug therapies, including single DSUR for fixed-dose combinations and multiple DSURs with justifications, covering IMPs like paclitaxel and carboplatin and data in section 8.5.

Master DSUR and PBRER submission timelines and frequencies, including data lock point and 60-day post data log point windows, plus parallel documents with benefit-risk and efficacy details.

Outline the dsur and pbrer process flow chart, detailing multi-stakeholder data collection, drafting, medical and peer reviews, sponsor feedback, and submission to regulatory authorities by day 50.

Explore the differences between DSUR and PBRER documents, their modular section structure, and how signals, risk evaluations, and integrated benefit risk analyses are organized for regulatory submissions.

Master the format and presentation of DSR and Pablo documents by navigating the 20 to 21 section structure, appendices, and key guideline references such as E12.

Learn to craft dsur and pbrer documents, assembling the dsur title page, executive summary, and introduction, and action taken sections, with ib and protocol references, and safety-focused approvals and signatories.

Present how to update reference safety information and investigator brochure, document adverse reactions, and align IP version and effective date for DSUR and PBRER sections four to five.

Explore DSUR section 6 on estimated cumulative exposure, detailing cumulative subject exposure in development programs and patient exposure from marketing experience, with line listings, tabular data, and demographic breakdowns.

Describe how DSUR section 7 organizes line listings of serious adverse events during the reporting period and the cumulative summary tabulations to the data log point, with Meddra coding.

Explore DSUR sections 8 to 10, summarizing significant findings from completed and ongoing clinical trials, long-term follow-up, other therapeutic uses, combination therapies, non-interventional study safety, and cross-trial safety data.

Explore DSUR sections 11 to 15, focusing on safety findings from marketing experience, negative statements, non-clinical data, literature updates, other DSR, and lack of efficacy.

Learn DSUR sections 16 to 17 by detailing region-specific appendices for US, Canada, EU, and China, compiling seven standard appendices, and tracking SARS, deaths, and late breaking information.

Assess the overall safety assessment and benefit–risk considerations in DSUR sections 18 to 20, detailing new safety concerns, risk factors, and adverse events.

Explore the additional sections of PBRER, including sections 15 through 19, and learn how to organize signals, risk evaluation, benefit evaluation, and appendix content in tabular pharmacovigilance documents.

Learn to perform the integrated benefit–risk analysis for approved indications in DSUR and PBRER, detailing medical need, alternatives, and evaluation using standard statements and templates.

Explore the objective and scope of periodic adverse drug experience reports, outline PADAR preparation steps and timeline (quarterly for three years, then annually), and compare PADAR with PBRER.

Learn the step-by-step process for preparing and submitting quarterly and annual pader reports, from data lock points and stakeholder coordination to drafting, review, and final submission.

Master step-by-step training on PADER documents, detailing the five sections—introductory paragraph, summary of tabulations, regulatory section, conclusion, and appendices—and how to document NDA numbers, MedDRA versions, and line listings.

Learn to compose comprehensive clinical study reports and patient safety narratives for regulatory submissions in pharmacovigilance. Understand CSR structure, the 16 sections, and key safety evaluation topics including section 12.3.2.

Explore the key purpose and structure of CSR per ICH E3 guidelines, including safety evaluation, patient safety narratives, and appendices, for regulatory submissions to FDA and EMA.

Contrast icsr narrative with csr patient safety narrative, clarifying external event reports, source documents, and regulatory expectations in pharmacovigilance for clinical trials and post-marketing cases.

Explore PBRER sections 1–5 and key pharmacovigilance concepts like DLP, IBD, and DSR, and learn how to craft the executive summary, estimate exposure, and report safety actions for aggregate writing.

Summarizes how to compile PBRER sections 6 to 14 with summary tabulations, reference information, clinical trial adverse events, post-marketing data, and MedDRA coding by SOC and preferred term.